1279692-45-3

Upstream product

• 1279692-43-1 2-[6-(4-fluorophenylamino)-2-(methylthio)pyrimidin-4-yl]ethanol 
• 920490-05-7 6-(2-hydroxyethyl)-2-(methylthio)-4-pyrimidinyl 4-methyl-1-benzenesulfonate 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1279692-47-5 6-[2-(tert-butyldiphenylsilyloxy)ethyl]-N-(4-fluorophenylamino)-2-(methylsulfonyl)pyrimidin-4-amine 
• 1279692-48-6 6-[2-(tert-butyldiphenylsilyloxy)ethyl]-N-(4-fluorophenylamino)-2-hydrazynylpyrimidin-4-amine 
• 1279692-49-7 2-[(2-{4-[2-(tert-butyldiphenylsilyloxy)ethyl]-6-(4-fluorophenylamino)pyrimidin-2-yl}hydrazono)methyl]phenol 
• 1279692-20-4 2-({2-[4-(4-fluorophenylamino)-6-(2-hydroxyethyl)pyrimidin-2-yl]hydrazono}methyl)phenol 

Relevant academic research and scientific papers

COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF

The present invention relates to the medical use of the compound of formula 1,2,3 or 4

Toward the Discovery of Novel Anti-HIV Drugs. Second-Generation Inhibitors of the Cellular ATPase DDX3 with Improved Anti-HIV Activity: Synthesis, Structure-Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation

A hit optimization protocol applied to the first nonnucleoside inhibitor of the ATPase activity of human DEAD-box RNA helicase DDX3 led to the design and synthesis of second-generation rhodanine derivatives with better inhibitory activity toward cellular DDX3 and HIV-1 replication. Additional DDX3 inhibitors were identified among triazine compounds. Biological data were rationalized in terms of structure-activity relationships and docking simulations. Antiviral activity and cytotoxicity of selected DDX3 inhibitors are reported and discussed. A thorough analysis confirmed human DDX3 as a valid anti-HIV target. The compounds described herein represent a significant advance in the pursuit of novel drugs that target HIV-1 host cofactors.